SEC Tracker
Get the app
ARDX · XBRL financial data

Ardelyx financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (ARDX's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Revenue from contracts with customers34*467398116*7498110125*94121128
Cost of goods and services sold5*791618*1212411*565
Research and development10*11131514*15161823*202625
Selling, general and administrative48*53656576*83848486*10210194
Operating income (loss)(28)*(25)(14)28*(36)(14)55*(33)(12)4
Interest expense2*2334*4466*656
Income tax expense (benefit)0*0000*1000*000
Net income (loss)(29)*(27)(16)(1)5*(41)(19)(1)(0)*(38)(17)(1)
Earnings per share, basic USD per share(0.12)*(0.11)(0.07)0.000.02*(0.17)(0.08)0.000.00*(0.15)(0.07)0.00
Earnings per share, diluted USD per share(0.13)*(0.11)(0.07)0.000.02*(0.17)(0.08)0.000.00*(0.15)(0.07)0.00
Weighted average shares, basic millions of shares232*233235236237*239240242244*246248250
Weighted average shares, diluted millions of shares227*233235236237*239240242244*246248250

Balance sheet

CSV

Fiscal quarters (ARDX's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Cash and cash equivalents213642476531904368319746
Marketable securities163166144143185183148200197207185239
Accounts receivable2228375358466377728310093
Inventory4979838591106123129123128139158
Prepaid and other current assets81211121115161514241921
Total current assets246258263284356313352368382382442441
Property and equipment, net111112222222
Right-of-use asset654424555444
Total assets298342343368436410467486502505576588
Accounts payable111711161614221819283834
Total current liabilities505762707876828389110132128
Lease liability, non-current211113444332
Total liabilities131191196210262265327332335356427423
Accumulated deficit(846)(873)(889)(890)(885)(926)(946)(947)(947)(985)(1,001)(1,002)
Total stockholders' equity167151147158173146140154167149149164
Total liabilities and equity298342343368436410467486502505576588
Common shares outstanding (cover page) millions of shares233234235237238239241243245247249251

Cash flows

CSV

Fiscal quarters (ARDX's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Net income (loss)(29)*(27)(16)(1)5*(41)(19)(1)(0)*(38)(17)(1)
Stock-based compensation4*811*9*10*1212*13*12*1415*15*
Depreciation and amortization0*01*1*1*11*1*1*11*1*
Net cash from operating activities(9)*(36)(19)*1*10*(38)(25)*0*21*(32)(6)*2*
Purchases of property and equipment0*00*0*1*01*0*0*00*0*
Net cash from investing activities(30)*(3)24*2*(42)*335*(51)*4*(10)23*(54)*
Proceeds from issuing common stock(0)*00*0*0*———year only———
Net cash from financing activities26*532*3*49*150*3*1*550*1*
Net change in cash(12)*156*6*18*(34)59*(47)*25*(37)66*(51)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Ardelyx46128not reported251.4M— 10-QSep 30, 2026
Collegium Pharmaceutical12920071*32.6M— 10-QJun 30, 2026
CorMedix25710286*77.9M— 10-QJun 30, 2026
Viridian Therapeutics165not reported(105)*113.3M9.3 quarters 10-QJun 30, 2026
Akebia Therapeutics156493.5*277.1M— 10-QJun 30, 2026
Neogen17222313218.3M— 10-QAug 31, 2026
Intellia Therapeutics1067.7(83)*140.1M5.3 quarters 10-QJun 30, 2026
Geron6357(16)*642.5M4.0 quarters 10-QJun 30, 2026
Aurinia Pharmaceuticals468446*134.0M— 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.